ATHE Articles, Alterity Therapeutics Limited

– ATH434 Improved Motor Performance and General Function in a Primate Model of Parkinson's Disease – – ATH434-201 Phase 2 Baseline Data...

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the P...

MELBOURNE, Australia and SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Co...

MELBOURNE, Australia and SAN FRANCISCO, March 27, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited ((ASX: ATH, NASDAQ:ATHE) ("Alterity" ...

– Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease to be Presented at International Conference – – Baseline ...

MELBOURNE, Australia and SAN FRANCISCO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Com...

MELBOURNE, Australia and SAN FRANCISCO, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Com...

Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results. Daktronics posted quarterly ...

Shares of GitLab Inc. (NASDAQ: GTLB) rose sharply in pre-market trading after the company posted better-than-expected results for its third quarte...

MELBOURNE, Australia and SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Com...